Gadgeel S - Search Results

1

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, Chin E, Parks M, Lee D, DiCecca RH, Lockerman E, Huynh T, Logan J, Ritterhouse LL, Le LP, Muniappan A, Digumarthy S, Channick C, Keyes C, Getz G, Dias-Santagata D, Heist RS, Lennerz J, Sequist LV, Benes CH, Iafrate AJ, Mino-Kenudson M, Engelman JA, Shaw AT. Gainor JF, et al. Among authors: gadgeel s. Cancer Discov. 2016 Oct;6(10):1118-1133. doi: 10.1158/2159-8290.CD-16-0596. Epub 2016 Jul 18. Cancer Discov. 2016. PMID: 27432227 Free PMC article.

2

Cost-effectiveness and lung cancer clinical trials.

Du W, Reeves JH, Gadgeel S, Abrams J, Peters WP. Du W, et al. Among authors: gadgeel s. Cancer. 2003 Oct 1;98(7):1491-6. doi: 10.1002/cncr.11659. Cancer. 2003. PMID: 14508837 Free article.

3

Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung cancer.

Wozniak AJ, Belzer K, Heilbrun LK, Kucuk O, Gadgeel S, Kalemkerian GP, Venkatramanamoorthy R, Kraut MJ. Wozniak AJ, et al. Among authors: gadgeel s. Clin Lung Cancer. 2007 Mar;8(5):313-8. doi: 10.3816/CLC.2007.n.010. Clin Lung Cancer. 2007. PMID: 17562230 Clinical Trial.

4

Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.

Gadgeel SM, Ali S, Philip PA, Ahmed F, Wozniak A, Sarkar FH. Gadgeel SM, et al. Cancer. 2007 Dec 15;110(12):2775-84. doi: 10.1002/cncr.23100. Cancer. 2007. PMID: 17948911 Free article. Retracted.

5

Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.

Gadgeel SM, Ali S, Philip PA, Wozniak A, Sarkar FH. Gadgeel SM, et al. Cancer. 2009 May 15;115(10):2165-76. doi: 10.1002/cncr.24250. Cancer. 2009. PMID: 19288574 Free article. Retracted.

6

Parameters for individualizing systemic therapy in non-small cell lung cancer.

Gadgeel SM, Cote ML, Schwartz AG, Matherly LH, Wozniak A, Bepler G. Gadgeel SM, et al. Drug Resist Updat. 2010 Dec;13(6):196-204. doi: 10.1016/j.drup.2010.10.001. Epub 2010 Nov 3. Drug Resist Updat. 2010. PMID: 21051275 Free PMC article. Review.

7

Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trials.

Gadgeel SM, Ivy P, Chen W, Mauer J, Smith D, Lorusso P. Gadgeel SM, et al. Clin Lung Cancer. 2011 Jul;12(4):218-23. doi: 10.1016/j.cllc.2011.03.022. Epub 2011 Apr 24. Clin Lung Cancer. 2011. PMID: 21726820

8

Crizotinib: an anaplastic lymphoma kinase inhibitor.

Gadgeel SM, Bepler G. Gadgeel SM, et al. Future Oncol. 2011 Aug;7(8):947-53. doi: 10.2217/fon.11.77. Future Oncol. 2011. PMID: 21823889

9

Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer.

Gadgeel SM. Gadgeel SM. Clin Lung Cancer. 2012 Mar;13(2):96-106. doi: 10.1016/j.cllc.2011.08.006. Epub 2011 Nov 6. Clin Lung Cancer. 2012. PMID: 22056889 Review.

10

Treatment of lung cancer.

Gadgeel SM, Ramalingam SS, Kalemkerian GP. Gadgeel SM, et al. Radiol Clin North Am. 2012 Sep;50(5):961-74. doi: 10.1016/j.rcl.2012.06.003. Radiol Clin North Am. 2012. PMID: 22974781 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

252 results

Search Page